Neuroendocrine tumors (NETs) are rare neoplasms with a relatively slow clinical course but a tendency to metastasize. Breast metastases from the gastrointestinal tract are extremely rare. We report a case of a 45-year-old woman with a breast metastasis from a small intestinal NET. In May 2019, mammography showed a BI-RADS 4 breast lesion, and core needle biopsy initially revealed triple-negative invasive carcinoma of no special type (NST). After breast-conserving surgery, histopathological examination demonstrated a grade 1 NET. Several months later, the patient underwent right hemicolectomy for a grade 2 ileal NET with regional lymph node metastases. Positive CDX2 expression in the breast specimen confirmed metastasis from the small intestine rather than primary breast carcinoma. The patient received combined treatment and remains under regular oncological and endocrinological follow-up. As of 2026, she remains in good general condition without evidence of recurrence or progression. Keywords: Neuroendocrine tumor breast metastasis neoplasm metastasis differential diagnosis case report
Breast cancer is one of the most commonly diagnosed malignant tumors worldwide and represents a significant public health problem. This paper presents the characteristics of the disease, with particular emphasis on risk factors, mechanisms of development, and molecular classification. Current diagnostic methods and available therapeutic strategies, such as surgery, chemotherapy (CT), radiotherapy (RT), and targeted therapies, are discussed. Particular attention is given to nanotechnology as a promising direction for the development of modern medicine. The potential applications of nanoparticles (NPs) in the diagnosis and treatment of breast cancer are presented, taking into account their mechanisms of action, potential clinical benefits, and limitations related to safety and efficacy. NPs may contribute to increased diagnostic precision and therapeutic efficacy, indicating their significant potential in the future of oncology.